Macular Telangiectasia Type 1 Managed With Long-Term Aflibercept Therapy

Jaclyn L Kovach; Harald Hess; Philip J Rosenfeld

doi:10.3928/23258160-20160601-14

Back

Macular Telangiectasia Type 1 Managed With Long-Term Aflibercept Therapy

Journal article

Peer reviewed

Macular Telangiectasia Type 1 Managed With Long-Term Aflibercept Therapy

Jaclyn L Kovach, Harald Hess and Philip J Rosenfeld

Ophthalmic surgery, lasers & imaging retina, Vol.47(6), pp.593-595

2016-06-01

DOI: https://doi.org/10.3928/23258160-20160601-14

PMID: 27327292

Abstract

Follow-Up Studies

Intravitreal Injections

Fluorescein Angiography - methods

Retinal Telangiectasis - diagnosis

Humans

Middle Aged

Male

Tomography, Optical Coherence - methods

Visual Acuity

Retinal Telangiectasis - drug therapy

Receptors, Vascular Endothelial Growth Factor - administration & dosage

Retinal Telangiectasis - complications

Macular Edema - etiology

Time Factors

Macular Edema - diagnosis

Macular Edema - drug therapy

Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors

Fundus Oculi

Recombinant Fusion Proteins - administration & dosage

Macula Lutea - pathology

A 60-year-old man diagnosed with macular telangiectasia type 1 (MacTel 1) was treated for 3 years with monthly aflibercept (Eylea; Regeneron, Tarrytown, NY) and serially imaged with spectral-domain optical coherence tomography. When administered monthly, aflibercept appeared to have a beneficial effect on macular edema secondary to MacTel 1. Visual acuity preservation despite minimal chronic macular edema could be attributed to the lack of significant photoreceptor disruption. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:593-595.].

Metrics

23 Record Views

3 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.36 Ophthalmology; 1.36.383 Diabetic Retinopathy
Web Of Science research areas: Ophthalmology; Surgery
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Macular Telangiectasia Type 1 Managed With Long-Term Aflibercept Therapy
Creators: Jaclyn L Kovach
Harald Hess
Philip J Rosenfeld
Publication Details: Ophthalmic surgery, lasers & imaging retina, Vol.47(6), pp.593-595
Publisher: United States
Grant note: P30 EY014801 / NEI NIH HHS
Academic Unit: Miller School of Medicine; UMMG Department of Ophthalmology
Language: English
Resource Type: Journal article
PMID: 27327292
Record Identifier: 991031577836702976